Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurocritical Care
Published in: Neurocritical Care 2/2017

01-10-2017 | Review Article

Drug Interactions in Neurocritical Care

Authors: Brian Spoelhof, Salia Farrokh, Lucia Rivera-Lara

Published in: Neurocritical Care | Issue 2/2017

Login to get access

Abstract

Drug–drug interactions (DDIs) are common and avoidable complications that are associated with poor patient outcomes. Neurocritical care patients may be at particular risk for DDIs due to alterations in pharmacokinetic profiles and exposure to medications with a high DDI risk. This review describes the principles of DDI pharmacology, common and severe DDIs in Neurocritical care, and recommendations to minimize adverse outcomes. A review of published literature was performed using PubMed by searching for ‘Drug Interaction’ and several high DDI risk and common neurocritical care medications. Key medication classes included anticoagulants, antimicrobials, antiepileptics, antihypertensives, sedatives, and selective serotonin reuptake inhibitors. Additional literature was also reviewed to determine the risk in neurocritical care and potential therapeutic alternatives. Clinicians should be aware of interactions in this setting, the long-term complications, and therapeutic alternatives.
Literature
1.
Moura C, Acurcio F, Belo N. Drug–drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266–72.CrossRefPubMed
2.
Papadopoulos J. Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations. In: Papadopoulos J, Cooper B, Kane-Gill S, Corbett SM, Jeffrey B, editors. Drug-induced complications in the critically ill patient: a guide for recognition and treatment. 1st ed. Mt Prospect: Society of Critical Care Medicine; 2012. p. 401–12.
3.
Uijtendaal EV, Van Harssel LLM, Hugenholtz GWK, et al. Analysis of potential drug–drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34(3):213–9.CrossRefPubMed
4.
Smithburger PL, Kane-Gill SL, Seybert AL. Drug–drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. Int J Pharm Pract. 2012;20(6):402–8.CrossRefPubMed
5.
Smithburger PL, Kane-Gill SL, Seybert AL. Drug–drug interactions in cardiac and cardiothoracic intensive care units: An analysis of patients in an academic medical centre in the US. Drug Saf. 2010;33(10):879–888.
6.
Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002;300(3):1036–1045. Accessed 7 Sept 2016.
7.
Derelanko M, Hollinger M. Metabolism and toxicokinetics of xenobiotics. In: Derelanko M, Hollinger M, editors. Handbook of toxicology. 1st ed. New York: CRC Press; 1995. p. 539–79.
8.
Brandon EFA, Raap CD, Meijerman I, Beijnen JH, Schellens JHM. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol. 2003;189(3):233–246. Accessed 7 Sept 2016.
9.
Kacew S, Lee B-M. Biotransformation of Toxicants. Lu’s Basic Toxicology: Fundamentals, Target Organs, and Risk Assessment, Sixth Edition. 4th ed. New York: Taylor and Francis; 2002. p. 26–37.
10.
DiPiro J, editor. Pharmacotherapy: a pathophysiologic approach. 4th ed. Stamford: Appleton & Lange; 1999.
11.
Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician. 1998;57(1):107–116. Accessed 7 Sept 2016.
12.
Goodman L, Limbird L, Milnoff P, Gilman A, Hardman J, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 1996.
13.
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41–57.CrossRefPubMed
14.
Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 18(1):84–112. Accessed 7 Sept 2016.
15.
Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391–396. Accessed 7 Sept 2016.
16.
Belpaire FM, Bogaert MG. Cytochrome P450: genetic polymorphism and drug interactions. Acta Clin Belg. 1996;51(4):254–260. Accessed 7 Sept 2016.
17.
Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 1997;8(3):161–70.CrossRefPubMed
18.
van Helvoort A, Smith AJ, Sprong H, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 1996;87(3):507–517. Accessed 7 Sept 2016.
19.
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84(21):7735–7738. Accessed 7 Sept 2016.
20.
Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990;38(9):1277–1287. Accessed 7 Sept 2016.
21.
Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005;36(3):583–7.CrossRefPubMed
22.
Tartara A, Galimberti CA, Manni R, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol. 1991;32(3):335–40.CrossRefPubMedPubMedCentral
23.
Sandow N, Diesing D, Sarrafzadeh A, Vajkoczy P, Wolf S. Nimodipine dose reductions in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2016;25(1):29–39.CrossRef
24.
Murphy-Human T, Welch E, Zipfel G, Diringer MN, Dhar R. Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage. World Neurosurg. 2011;75(2):269–74.CrossRefPubMed
25.
Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010;12(2):165–172.
26.
Meisheri YV. Simultaneous phenytoin and warfarin toxicity on chronic concomitant therapy. J Assoc Physicians India. 1996;44(9):661–662. Accessed 7 Sept 2016.
27.
Hansen JM, Kristensen M, Skovsted L, Christensen LK. Dicoumarol-induced diphenylhydantoin intoxication. Lancet. 1966;2(7457):265–266. Accessed 7 Sept 2016.
28.
Hassan Y, Awaisu A, Aziz NA, Ismail O. The complexity of achieving anticoagulation control in the face of warfarin–phenytoin interaction: an Asian case report. Pharm World Sci. 2005;27(1):16–19. Accessed 7 Sept 2016.
29.
Wiggins BS, Northup A, Johnson D, Senfield J. Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin. Pharmacotherapy. 2016;36(2):e5–7.CrossRefPubMed
30.
Altena R, van Roon E, Folkeringa R, de Wit H, Hoogendoorn M. Clinical challenges related to novel oral anticoagulants: drug–drug interactions and monitoring. Haematologica. 2014;99(2):e26–7.CrossRefPubMedPubMedCentral
31.
Nolan PE, Marcus FI, Hoyer GL, Bliss M, Gear K. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin Pharmacol Ther. 1989;46(1):43–9.CrossRefPubMed
32.
Nolan PE, Erstad BL, Hoyer GL, Bliss M, Gear K, Marcus FI. Steady-state interaction between amiodarone and phenytoin in normal subjects. Am J Cardiol. 1990;65(18):1252–7.CrossRefPubMed
33.
McGOVERN B. Possible interaction between amiodarone and phenytoin. Ann Intern Med. 1984;101(5):650.CrossRefPubMed
34.
Gore JM, Haffajee CI, Alpert JS. Interaction of amiodarone and diphenylhydantoin. Am J Cardiol. 1984;54(8):1145.CrossRefPubMed
35.
Nolan PE, Marcus FI, Karol MD, Hoyer GL, Gear K. Effect of phenytoin on the clinical pharmacokinetics of amiodarone. J Clin Pharmacol. 1990;30(12):1112–9.CrossRefPubMed
36.
Chung J-Y, Cho J-Y, Yu K-S, et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005;77(6):486–94.CrossRefPubMed
37.
Anderson GD, Gidal BE, Kantor ED, Wilensky AJ. Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver. Epilepsia. 35(1):221–225. Accessed 7 Sept 2016.
38.
Samara EE, Granneman RG, Witt GF, Cavanaugh JH. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. J Clin Pharmacol. 1997;37(5):442–450. Accessed 7 Sept 2016.
39.
Calvo R, Suárez E, Rodríguez-Sasiaín JM, Aguilera L. Effect of sodium valproate on midazolam distribution. J Pharm Pharmacol. 1988;40(2):150–152. Accessed 15 Sept 2016.
40.
Katz AM. Pharmacology and mechanisms of action of calcium-channel blockers. J Clin Hypertens. 1986;2(3 Suppl):28S–37S. Accessed 7 Sept 2016.
41.
Scholz H. Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther. 1997;10 Suppl 3:869–872. Accessed 7 Sept 2016.
42.
Zhou S-F, Xue CC, Yu X-Q, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687–710.CrossRefPubMed
43.
Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000;17(10):1189–1197. Accessed 7 Sept 2016.
44.
Bahls FH, Ozuna J, Ritchie DE. Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. Neurology. 1991;41(5):740–742. Accessed 7 Sept 2016.
45.
Clarke WR, Horn JR, Kawabori I, Gurtel S. Potentially serious drug interactions secondary to high-dose diltiazem used in the treatment of pulmonary hypertension. Pharmacotherapy. 13(4):402–405. Accessed 7 Sept 2016.
46.
Wijdicks EF, Torres VE, Schievink WI, Sterioff S. Cerebral hemorrhage in recipients of renal transplantation. Mayo Clin Proc. 1999;74(11):1111–2.CrossRefPubMed
47.
Wijdicks EF, de Groen PC, Wiesner RH, Krom RA. Intracerebral hemorrhage in liver transplant recipients. Mayo Clin Proc. 1995;70(5):443–6.CrossRefPubMed
48.
Wang WL, Yang ZF, Lo CM, Liu CL, Fan ST. Intracerebral hemorrhage after liver transplantation. Liver Transpl. 2000;6(3):345–8.CrossRefPubMed
49.
Liu-DeRyke X, Levy PD, Parker D, Coplin W, Rhoney DH. A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke. Neurocrit Care. 2013;19(1):41–7.CrossRefPubMed
50.
Liu-Deryke X, Janisse J, Coplin WM, Parker D, Norris G, Rhoney DH. A comparison of nicardipine and labetalol for acute hypertension management following stroke. Neurocrit Care. 2008;9(2):167–76.CrossRefPubMed
51.
Iaria P, Blacher J, Asplanato M, Edric K, Safar M, Girerd X. [A new cause of resistant arterial hypertension: coprescription with anticonvulsant treatments]. Arch Mal Coeur Vaiss. 1999;92(8):1005–1008. Accessed 7 Sept 2016.
52.
Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027–1052. Accessed 7 Sept 2016.
53.
Wu C-C, Pai T-Y, Hsiao F-Y, Shen L-J, Lin Wu F-L. The effect of different carbapenem antibiotics (ertapenem, imipenem/cilastatin and meropenem) on serum valproic acid concentrations. Ther Drug Monit. 2016;38(5):587–92.CrossRefPubMed
54.
Coves-Orts FJ, Borrás-Blasco J, Navarro-Ruiz A, Murcia-López A, Palacios-Ortega F. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother. 2005;39(3):533–7.CrossRefPubMed
55.
Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy. 2007;27(8):1202–5.CrossRefPubMed
56.
Taha FA, Hammond DN, Sheth RD. Seizures from valproate–carbapenem interaction. Pediatr Neurol. 2013;49(4):279–81.CrossRefPubMed
57.
Kojima S, Nadai M, Kitaichi K, Wang L, Nabeshima T, Hasegawa T. Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. Antimicrob Agents Chemother. 1998;42(12):3136–3140. Accessed 7 Sept 2016.
58.
Yokogawa K, Iwashita S, Kubota A, et al. Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. Pharm Res. 2001;18(9):1320–1326. Accessed 7 Sept 2016.
59.
Yamamura N, Imura K, Naganuma H, Nishimura K. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. Drug Metab Dispos. 1999;27(6):724–730. Accessed 7 Sept 2016.
60.
Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Physician. 2000;61(6):1745–1754. Accessed 7 Sept 2016.
61.
Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. 2013;158(12):869–76.CrossRefPubMed
62.
63.
Choi HA, Ko S-B, Presciutti M, et al. Prevention of shivering during therapeutic temperature modulation: the Columbia anti-shivering protocol. Neurocrit Care. 2011;14(3):389–94.CrossRefPubMed
64.
Morrison EK, Rowe AS. Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia. J Clin Pharm Ther. 2012;37(5):610–3.CrossRefPubMed
65.
Ziesenitz VC, König SK, Mahlke NS, Skopp G, Haefeli WE, Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol. 2015;55(6):708–17.CrossRefPubMed
66.
Hillman AD, Witenko CJ, Sultan SM, Gala G. Serotonin syndrome caused by fentanyl and methadone in a burn injury. Pharmacotherapy. 2015;35(1):112–7.CrossRefPubMed
67.
Katus LE, Frucht SJ. Management of serotonin syndrome and neuroleptic malignant syndrome. Curr Treat Options Neurol. 2016;18(9):39.CrossRefPubMed
68.
Mowry JB, Spyker DA, Cantilena LR, Bailey JE, Ford M. 2012 annual report of the american association of poison control centers’ national poison data system (NPDS): 30th annual report. Clin Toxicol (Phila). 2013;51(10):949–1229.CrossRef
69.
Ailawadhi S, Sung K-W, Carlson LA, Baer MR. Serotonin syndrome caused by interaction between citalopram and fentanyl. J Clin Pharm Ther. 2007;32(2):199–202.CrossRefPubMed
70.
Goodwin HE, Gill RS, Murakami PN, Thompson CB, Lewin JJ, Mirski MA. Dexmedetomidine preserves attention/calculation when used for cooperative and short-term intensive care unit sedation. J Crit Care. 2013;28(6):1113.e7–1113.e10.
71.
Stiehl SR, Squires JE, Bucuvalas JC, Hemmelgarn TS. Tacrolimus interaction with dexmedetomidine—a case report. Pediatr Transplant. 2016;20(1):155–7.CrossRefPubMed
72.
Mead GE, Hsieh C-F, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. In: Mead GE, editor. Cochrane database of systematic reviews. Chichester: Wiley; 2012.
73.
DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994;55 Suppl 38:45–7. Accessed 7 Sept 2016.
74.
Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32 Suppl 1:1–21. Accessed 7 Sept 2016.
75.
Chollet F, Tardy J, Albucher J-F, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123–30.CrossRefPubMed
76.
Wang Z-Y, Chen M, Zhu L-L, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015;11:449–67.PubMedPubMedCentral
77.
de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function. Drugs Aging. 2011;28(5):345–67.CrossRefPubMed
78.
Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011;33(4):433.CrossRefPubMedPubMedCentral
79.
Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. Can Med Assoc J. 2011;183(16):1835.CrossRef
80.
Nelson MH, Birnbaum AK, Remmel RP. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res. 2001;44(1):71–82. Accessed 7 Sept 2016.
81.
Flockhart DA. Drug interactions: cytochrome p450 drug interaction table. Indiana University School of Medicine. 2007. “/clinpharm/ddis/clinical-table/” Accessed 25 Nov 2016.
Metadata
Title
Drug Interactions in Neurocritical Care
Authors
Brian Spoelhof
Salia Farrokh
Lucia Rivera-Lara
Publication date
01-10-2017
Publisher
Springer US
Published in
Neurocritical Care / Issue 2/2017
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-016-0369-0

Other articles of this Issue 2/2017

Neurocritical Care 2/2017 Go to the issue

Original Article

Anxiety and Depressive Symptoms Among Two Seriously Medically Ill Populations and Their Family Caregivers: A Comparison and Clinical Implications

Review Article

Nutritional and Bioenergetic Considerations in Critically Ill Patients with Acute Neurological Injury

Practical Pearl

Dual-Energy CT to Diagnose Pseudoedema in Contrast-Induced Encephalopathy Following Cerebral Angiography

Neuroimage

Coxsackie B3/B4-Related Acute Flaccid Myelitis

Review Article

Management of Acute Hypertensive Response in Intracerebral Hemorrhage Patients After ATACH-2 Trial

Editorial

Caring for Patients’ Families (or Lack of Family) in Neurocritical Care